Xenitra has returned to positive quarterly gross profit as its new pharmaceutical and Web3 businesses begin generating revenue, but statutory operating cash flow remained negative at A$790,000. The company is now relying on procurement targets, repeat Web3 sales and further capital discipline to turn early commercial activity into sustainable cash generation.
